ArticleScientific reports2025
Hydroxysafflor Yellow A modulation of metabolite networks and inhibition of JAK2/STAT1 pathway in sepsis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Taoren Honghua Jian Regulate NLRP3 Inflammasome of Coronary Artery Disease Patients: A Multi-Center, Double-Blind, Randomized Controlled Trial.Vascular health and risk management · 2026Trial
- Emerging natural product development strategies drive the therapeutic potential exploration and clinical translation of hydroxysafflor yellow A.Journal of pharmaceutical analysis · 2026Review
- Karacoline attenuates sepsis-induced acute lung injury by suppressing apoptosis via PPARγ-associated inhibition of JNK/ERK MAPK signaling.Respiratory research · 2026Article
- Hydroxysafflor Yellow A Attenuates Sepsis-Induced Cardiac Dysfunction by Inhibiting Ferroptosis via Activation of Thioredoxin.Cardiovascular toxicology · 2026Article
- Hydroxysafflor yellow A attenuates sepsis-induced intestinal barrier dysfunction by modulating Bcl-2/SOD2-mediated mitochondrial apoptosis.Frontiers in pharmacology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Sepsis, a severe infectious disease causing multiple organ dysfunction, requires further exploration of its pathomechanisms and therapeutic options. Hydroxysafflor Yellow A (HYSA), extracted from Carthamus tinctorius L, has shown anti-inflammatory and antioxidant properties effective in treating sepsis, though its precise mechanism remains unclear. In this study, a cecum ligation puncture (CLP) model was used to evaluate HYSA's effects on sepsis-induced organ injury. HYSA (300 mg/kg) was administered intraperitoneally 4 h post-CLP. Results showed that HYSA inhibited the inflammatory response and improved pathological scores in the liver, lungs, and kidneys. Metabolomics analysis identified key metabolites and pathways influenced by HYSA, including nicotinate and nicotinamide metabolism and glycine/serine metabolism. Network pharmacology and molecular docking identified JAK2/STAT1 as potential targets, with Western blotting confirmed that HYSA inhibits JAK2/STAT1 phosphorylation. These findings suggest that HYSA protects against sepsis-induced organ injury by regulating metabolic networks and modulating the JAK2/STAT1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.